The contract research organization (CRO) Vector Oncology undertakes early phase immunotherapy trials as well as late phase diagnostic and combination products.
Cancer trials of particular interest for the Asia-Pacific region include “breast cancer, lung cancer, melanoma and those with high prevalence in Asia – gastric, hepatic and head and neck cancers,” George Clinical CEO Dr. Marisa Petersen, told Outsourcing-Pharma.com
The acquisition also extends the firm’s experience in chronic disease research to the US, Petersen told us. Including therapeutic areas such as neurological, cardiovascular, renal, respiratory and epidemiological disease.
“Whilst trials are increasingly run globally and our potential to recruit in the Asia-Pacific region is important for Phase II and III studies, over 90% of our customers are US-based and require US sites and patients for their studies,” Petersen said.
Through the acquisition, George Clinical has also attained a strong pipeline of studies, the details of which were not disclosed.
Staff absorption
George Clinical is absorbing all 43 staff members from the Memphis- and Kansas-based facilities, including Vector Oncology’s Executive Vice President and Managing Director, Mr. Sean Hart, who will head George Clinical’s US operations and global late-phase research.
George Clinical is headquartered in Australia, with facilities in East Asia, China, India, and Europe.